Skip to content
The Cancer History Project
HOME
ABOUT
THE CANCER HISTORY PROJECT
THE CANCER LETTER
EDITORIAL BOARD
SPONSORS
CONTRIBUTORS
TCL ARCHIVES
LATEST ARTICLES
Search for:
Search
ARCHIVES
Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.
This article is from
The Cancer Letter
archive.
Vol. 30 No. 31 | July 30, 2004
Download PDF
Visit The Full Archive
Related Articles
TCL Archive
Includes May Business & Regulatory Report (8-page issue).
June 6, 2003
TCL Archive
FDA Advisors Debate Ban, Black Box And Status Quo of Power Morcellators
July 25, 2014
TCL Archive
Drug Development Effort Criticized
April 18, 1975
TCL Archive
FDA, ASCO Meet to Review Drug Approval Endpoints
April 25, 2003
TCL Archive
Garb’s Questions, Answers About Cancer Program
December 5, 1980
TCL Archive
News Council Says Post Series “Flawed By Sensationalism”
June 11, 1982